Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways

European Journal of Cancer Part A

Volumn 32, Issue 7, 1996, Pages 1248-1253

  Masters, J R W ^a   Thomas, R ^a   Hall, A G ^b   Hogarth, L ^b   Matheson, E C ^b   Cattan, A R ^b   Lohrer, H ^c  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

drug sensitivity; GSH; GST; metallothionein; testis tumour cells

Indexed keywords

CISPLATIN; DEXAMETHASONE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; METALLOTHIONEIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DETOXIFICATION; DRUG BLOOD LEVEL; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SURVIVAL TIME; TESTIS TUMOR; TUMOR CELL;

EID: 0030176141     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00033-0     Document Type: Article

References (60)

1. 1. Peckham MJ. Testicular cancer. Rev Oncol 1988, 1, 439-453.
2. 2. Einhorn LH, Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990, 8, 1777-1791.
3. 3. Raghavan D. Chemotherapy for advanced bladder cancer: 'Midsummer night's dream' or 'Much ado about nothing'? Br J Cancer 1990, 62, 337-340.
4. 4. Seidman AD, Scher HI. The evolving role of chemotherapy for muscle infiltrating bladder cancer. Semin Oncol 1991, 18, 585-595.
5. 5. Oosterhuis JW, Andrews PW, Knowles BB, Damjanov I. Effects of cis-platinum on embryonal carcinoma cell lines in vitro. Int J Cancer 1984, 34, 133-139.
6. 6. Walker MC, Parris CN, Masters JRW. Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs. J Natl Cancer Inst 1987, 79, 213-216.
7. 7. Pera MF, Friedlos F, Mills J, Roberts JJ. Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. Cancer Res 1987, 47, 6810-6813.
8. 8. Masters JRW, Osborne EJ, Walker MC, Parris CN. Hypersensitivity of human testis tumor cells in vitro to chemotherapeutic drugs. Int J Cancer 1993, 53, 340-346.
9. 9. Parris CN, Arlett CF, Lehmann AR, Green MHL, Masters JRW. Differential sensitivities to gamma radiation of human bladder and testicular tumour cell lines. Int J Radiat Biol 1988, 53, 599-608.
10. 10. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54, 4313-4320.
11. 11. Sark MW, Timmer-Bosscha H, Meijer C, et al. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour colon carcinoma cell lines. Br J Cancer 1995, 71, 684-690.
12. 12. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991, 64, 215-220.
13. 13. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992, 89, 3070-3074.
14. 14. Mitchell JB, Cook JA, DeGraff W, Glatstein E, Russo A. Keynote address: glutathione modulation in cancer treatment: will it work? Int J Radiat Oncol Biol Phys 1989, 16, 1289-1295.
15. 15. Waxman DJ. Glutathione-S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy - a review. Cancer Res 1990, 50, 6449-6454.
16. 16. Morrow CS, Cowan KH. Glutathione-S-transferases and drug resistance. Cancer Cells 1990, 2, 15-22.
17. 17. Rushmore TH, Pickett CB. Glutathione-S-transferases, structure, regulation, and therapeutic implications. J Biol Chem 1993, 268, 11,475-11,478.
18. 18. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988, 241, 1813-1815.
19. 19. Lohrer H, Robson T. Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis 1989, 10, 2279-2284.
20. 20. Satoh M, Cherain MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 1994, 54, 5255-5257.
21. 21. Masters JRW, Hepburn PJ, Walker L, et al. Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res 1986, 46, 3630-3636.
22. 22. Bubenik J, Baresova M, Viklicky V, Jacoubkova J, Sainerova H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 1973, 11, 765-773.
23. 23. Rasheed S, Gardner MB, Rongey RW, Nelson-Ress WA, Arnstein P. Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst 1977, 58, 881-890.
24. 24. Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure. Br J Cancer 1970, 24, 746-754.
25. 25. Hogan B, Fellous M, Avner P, Jacob F. Isolation of a human teratoma cell line which expresses F9 antigen. Nature 1977, 270, 515-518.
26. 26. Bronson DL, Andrews PW, Solter D, Cervenka J, Lange PH, Fraley EE. Cell line derived from a metastasis of a human testicular germ cell tumor. Cancer Res 1980, 40, 2500-2506.
27. 27. Pera MF, Blasco Lafita MJ, Mills J. Cultured stem-cells from human testicular teratomas: the nature of human embryonal carcinoma, and its comparison with two types of yolk-sac carcinoma. Int J Cancer 1987, 40, 334-343.
28. 28. Lower J, Lower R, Stegman J, Frank H, Kurth R. Retrovirus particle production in three of four human teratocarcinoma cell lines. In Neth R, Gallo RC, Graf T, Mannweilen K, Winkler K, eds. Haematology and Blood Transfusion, Vol. 26. Berlin, Springer, 1981.
29. 29. Vogelzang N, Andrew P, Bronson D. An extragonadal human embryonal carcinoma cell line (1618K). Proc Am Assoc Cancer Res 1983, 24, 3.
30. 30. Walker MC, Povey S, Parrington JM, Riddle PN, Knuechel R, Masters JRW. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines. Eur J Cancer 1990, 26, 742-747.
31. 31. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 1976, 72, 248-254.
32. 32. Colgreave IA, Moldeus P. Methodologies for the application of monobromobimane to the simultaneous analysis of soluble and protein thiol components of biological systems. J Biochem Biophys Meth 1986, 13, 231-249.
33. 33. Maung ZT, Hogarth L, Reid MM, Proctor SS, Hamilton PS, Hall AG. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukaemia. Leukaemia 1994, 8, 1487-1491.
34. 34. Hall A, Foster F, Proctor SJ, Cattan AR. Purification and characterisation of a pi class glutathione S-transferase from human leukaemic cells. Br J Haematol 1990, 76, 494-500.
35. 35. Eaton DL, Toal BF. Evaluation of the Cd/haemoglobin affinity assay for the rapid determination of metallothionein in biological tissues. Toxicol Appl Pharmacol 1982, 66, 134-142.
36. 36. Fry AM, Chresta CM, Davies SM, et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991, 51, 6592-6595.
37. 37. Parris CN, Walker MC, Masters JRW, Arlett CF. Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies. Cancer Res 1990, 50, 7513-7518.
38. 38. Bedford P, Fichtinger-Schepman AMJ, Shellard SA, Walker MC, Masters JRW, Hill BT. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 1988, 48, 3019-3024.
39. 39. Hill BT, Scanlon KJ, Hansson J, et al. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 1994, 30A, 832-837.
40. 6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines. Br J Cancer 1992, 66, 840-843.
41. 41. McLaughlin K, Coren G, Masters J, Brown R. Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines. Int J Cancer 1993, 53, 662-666.
42. 42. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cell 1990, 2, 35-43.
43. 43. Lai G-M, Ozols RF, Young RC, Hamilton TC. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 1989, 81, 535-539.
44. 44. Zaman GJ, Lankelma J, van Tellingen O, et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995, 92, 7690-7694.
45. 45. Kelland LR, Mistry P, Abel G, et al. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 1992, 52, 1710-1716.
46. 46. Timmer-Bosscha H, Timmer A, Meijer C, et al. Cis-diamminedichloroplatinum(II) resistance in vitro and in vivo in human embryonal carcinoma cells. Cancer Res 1993, 53, 5707-5713.
47. 47. Shellard SA, Hosking LK, Hill BT. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line. Biochem Pharmacol 1994, 47, 775-779.
48. 48. Nakagawa K, Sajo N, Tsuchida S, et al. Glutathione-S-transferase π as a determinant of drug resistance in transfectant cell lines. J Biol Chem 1990, 265, 4296-4301.
49. 49. Moscow JA, Fairchild CR, Madden MJ, et al. Expression of anioninc glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989, 49, 1422-1428.
50. 50. Lewis AD, Forrester LM, Hayes JD, et al. Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines. Br J Cancer 1989, 60, 327-331.
51. 51. Strohmeyer T, Klone A, Wagner G, Hartmann M, Sies H. Glutathione-S-transferases in human testicular germ cell tumors: changes of expression and activity. J Urol 1992, 147, 1424-1428.
52. 52. Klys HS, Whillis D, Howard G, Harrison DJ. Glutathione S-transferase expression in the human testis and testicular germ cell neoplasia. Br J Cancer 1992, 66, 589-593.
53. 53. Thomas DJ, Birch PJ, Vickers J, et al. Glutathione-S-transferase π expression in transitional cell carcinoma of the bladder. Br J Urol 1993, 72, 740-743.
54. 54. Kaina B, Lohrer H, Karin M, Herrlich P. Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents. Proc Natl Acad Sci USA 1990, 87, 2710-2714.
55. 55. Robson T, Hall A, Lohrer H. Increased sensitivity of a Chinese hamster ovary cell line to alkylating agents after overexpression of the human metallothionein II-A gene. Mutat Res 1992, 274, 177-185.
56. 56. Kotoh S, Naito S, Sakamoto N, Goto K, Kumazawa J. Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. J Urol 1994, 152, 1267-1270.
57. 57. Waller DP, Killinger JM, Zaneveld LJD. Physiology and toxicology of the male reproductive tract. In JA Thomas, ed. Endocrine Toxicology. New York, Raven Press, 1985, 269-333.
58. 58. Kreis IA, de Does M, Hoekstra JA, de-Lezenne-Coulander C, Peters PW, Wentink GH. Effects of cadmium on reproduction, an epizootologic study. Teratology 1993, 48, 189-196.
59. 59. Chin JL, Benerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, Cherian MG. Metallothionein in testicular germ cell tumours and drug resistance. Cancer 1993, 72, 3029-3035.
60. 60. Kondo Y, Kuo S-M, Watkins SC, Lazo JS. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 1995, 55, 474-477.